Browse result page of THPdb

The total number entries retrieved from this search are 23

ID	ThPPID	Name	Peptide Sequence	Length	Functional Classification	Disease	Brand	Company	Physical Appearance	Route of Administartion	Category	Target
ID1005	ThPPIDTh1002	NameCetuximab	Peptide SequenceHeavy chain:QVQLKQSG Full view	Length243	Functional ClassificationIIIc	DiseaseCancer	BrandErbitux	CompanyImClone Systems Inc	Physical AppearanceSterile, clear, colorless liquid of pH 7.0-7.4, which may contain a small amount of easily visible, white, amorphous cetuximab particulates	Route of AdministartionIntravenous infusion	CategoryAntineoplastic Agents	TargetEpidermal growth factor receptor,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c
ID1548	ThPPIDTh1117	NameIpilimumab	Peptide SequenceHeavy chain: QVQLVES Full view	Length663	Functional ClassificationIIIc	DiseaseCancer	BrandYERVOY	CompanyBristol-Myers Squibb	Physical AppearanceSterile, preservative-free, clear to slightly opalescent, colorless to pale-yellow solution	Route of AdministartionN.A.	CategoryAntineoplastic Agents and Monoclonal antibodies	TargetCytotoxic T-lymphocyte protein 4
ID1549	ThPPIDTh1118	NameSulodexide	Peptide SequenceN.A. Full view	Length0	Functional ClassificationIIIc	DiseaseHormonal/genetic/Hematological/N.A.	BrandSULODEXIDE	CompanySyntex S.A	Physical AppearanceN.A.	Route of AdministartionN.A.	CategoryAntithrombins and Fibrinolytic Agents and Hypoglycemic Agents and Anticoagulants and Hypolipidemic Agents	TargetHeparin cofactor 2,Antithrombin-III
ID1560	ThPPIDTh1121	NamePertuzumab	Peptide Sequencelight chain DIQMTQSP Full view	Length664	Functional ClassificationIIIc	DiseaseCancer	BrandPerjeta	CompanyGenentech	Physical AppearanceSterile, clear to slightly opalescent, colorless to pale brown liquid	Route of AdministartionIntravenous infusion	CategoryMonoclonal antibodies	TargetReceptor tyrosine-protein kinase erbB-2
ID1570	ThPPIDTh1123	NameDenosumab	Peptide SequenceHeavy chain EVQLLESG Full view	Length664	Functional ClassificationIIIc	DiseaseOsteological	BrandXgeva	CompanyAmgen.	Physical AppearanceSterile, preservative-free, clear, colorless to pale yellow solution	Route of AdministartionN.A.	CategoryBone Density Conservation Agents and Monoclonal antibodies	TargetTumor necrosis factor ligand superfamily member 11
ID1571	ThPPIDTh1123	NameDenosumab	Peptide SequenceHeavy chain EVQLLESG Full view	Length664	Functional ClassificationIIIc	DiseaseOsteological	BrandProlia	CompanyAmgen.	Physical AppearanceSterile, preservative-free, clear, colorless to pale yellow solution	Route of AdministartionN.A.	CategoryBone Density Conservation Agents and Monoclonal antibodies	TargetTumor necrosis factor ligand superfamily member 11
ID1600	ThPPIDTh1127	NameBuserelin	Peptide SequenceN.A. Full view	Length0	Functional ClassificationIIIc	DiseaseCancer/Hormonal	BrandSuprecur (Nasal Spray Solution)	CompanySanofi-Aventis	Physical Appearance150 micrograms Nasal Spray Solution	Route of AdministartionNasal spray	CategoryN.A.	TargetLutropin-choriogonadotropic hormone receptor,Gonadotropin-releasing hormone receptor
ID1601	ThPPIDTh1127	NameBuserelin	Peptide SequencepGlu-His-Trp-Ser-Tyr Full view	Length9	Functional ClassificationIIIc	DiseaseCancer/Hormonal	BrandSuprecur (injection)	CompanySanofi-Aventis	Physical Appearance1mg/ml Injection	Route of AdministartionSubcutaneous injection	CategoryN.A.	TargetLutropin-choriogonadotropic hormone receptor,Gonadotropin-releasing hormone receptor
ID1664	ThPPIDTh1156	NameAbarelix	Peptide SequenceN.A. Full view	Length0	Functional ClassificationIIIc	DiseaseHormonal	BrandPlenaxis	CompanySpeciality european pharma	Physical AppearanceWhite to off-white sterile dry powder	Route of AdministartionIntramuscular Injection	CategoryAnti-Testosterone Agents	TargetGonadotropin-releasing hormone receptor
ID1708	ThPPIDTh1170	NameBlinatumomab	Peptide SequenceDIQLTQSPASLAVSLGQRAT Full view	Length504	Functional ClassificationIIIc	DiseaseCancer/Genetic	BrandBlincyto	CompanyAMGEN	Physical AppearanceLyophilized Powder for intravenous administration	Route of AdministartionIntravenous	CategoryAntineoplastic Agents, Immunosuppressive Agents, Monoclonal antibodies, Antineoplastic and Immunomodulating Agents	TargetB-lymphocyte antigen CD19; T-cell surface glycoprotein CD3 delta chain
ID1724	ThPPIDTh1174	NameDaratumumab	Peptide SequenceNA Full view	Length0	Functional ClassificationIIIc	DiseaseCancer	BrandDarzalex	CompanyJanssen Biotech, Inc.	Physical AppearanceSolution, concentrate	Route of AdministartionIntravenous	CategoryAntineoplastic Agents	TargetADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
ID1738	ThPPIDTh1178	NameElotuzumab	Peptide Sequenceheavy chain EVQLVESG Full view	Length689	Functional ClassificationIIIc	DiseaseCancer	BrandNA	CompanyNA	Physical AppearanceInjection, Powder, Lyophilized, for Solution	Route of AdministartionIntravenous	CategoryNA	TargetSLAM family member 7
ID1739	ThPPIDTh1178	NameElotuzumab	Peptide Sequenceheavy chain EVQLVESG Full view	Length689	Functional ClassificationIIIc	DiseaseCancer	BrandEmpliciti	CompanyE.R. Squibb & Sons, L.L.C.	Physical AppearancePowder Lyophilized for Solution	Route of AdministartionIntravenous	CategoryNA	TargetSLAM family member 8
ID1740	ThPPIDTh1178	NameElotuzumab	Peptide Sequenceheavy chain EVQLVESG Full view	Length689	Functional ClassificationIIIc	DiseaseCancer	BrandEmpliciti	CompanyE.R. Squibb & Sons, L.L.C.	Physical AppearancePowder Lyophilized for Solution	Route of AdministartionIntravenous	CategoryNA	TargetSLAM family member 9
ID1753	ThPPIDTh1181	NameFilgrastim-sndz	Peptide SequenceNA Full view	Length0	Functional ClassificationIIIc	DiseaseCancer	BrandZarxio	CompanySandoz Inc	Physical AppearanceSolution	Route of AdministartionIntravenous; Subcutaneous	CategoryNA	TargetNA
ID1805	ThPPIDTh1199	NameRamucirumab	Peptide Sequenceramucirumab|Homo sap Full view	Length909	Functional ClassificationIIIc	DiseaseCancer	BrandCyramza	CompanyEli Lilly and Company	Physical AppearanceSolution	Route of AdministartionIntravenous	CategoryAntineoplastic and Immunomodulating Agents	TargetVascular endothelial growth factor receptor 2
ID1811	ThPPIDTh1202	NamePembrolizumab	Peptide SequenceHeavy Chain Sequence Full view	Length711	Functional ClassificationIIIc	DiseaseCancer	BrandKeytruda	CompanyMerck Sharp & Dohme Corp.	Physical AppearanceLyophilized Powder	Route of AdministartionIntravenous infusion	CategoryAntineoplastic and Immunomodulating Agents	TargetProgrammed cell death protein 1
ID1813	ThPPIDTh1204	NameOfatumumab	Peptide SequenceOfatumumab Heavy Cha Full view	Length483	Functional ClassificationIIIc	DiseaseCancer	BrandArzerra	CompanyGlaxo Smith Kline Llc	Physical AppearanceLiquid	Route of AdministartionIntravenous	CategoryAntineoplastic and Immunomodulating Agents	Target
ID1815	ThPPIDTh1206	NameNivolumab	Peptide SequenceHeavy Chain Sequence Full view	Length710	Functional ClassificationIIIc	DiseaseCancer	BrandOpdivo	CompanyE.R. Squibb & Sons, L.L.C.	Physical AppearanceLiquid	Route of AdministartionIntravenous	CategoryAntineoplastic and Immunomodulating Agents	TargetProgrammed cell death protein 1
ID1816	ThPPIDTh1207	NameNecitumumab	Peptide SequenceNA Full view	Length0	Functional ClassificationIIIc	DiseaseCancer	BrandPortrazza	CompanyEli Lilly and Company	Physical AppearanceSterile, preservative free, clear to slightly opalescent and colorless to slightly yellow Solution	Route of AdministartionIntravenous	CategoryNA	TargetNA
ID1837	ThPPIDTh1226	NameDinutuximab	Peptide SequenceNA Full view	Length0	Functional ClassificationIIIc	DiseaseCancer	Brandunituxin	CompanyNA	Physical Appearancesterile, preservative-free, clear/colorless to slightly opalescent solution	Route of AdministartionIntravenous	CategoryAntibody, Immunosuppresive agent, Antineoplastic agent	TargetGanglioside GD2 (small molecule)
ID1843	ThPPIDTh1231	NameIbritumomab tiuxetan	Peptide SequenceHeavy chain: QAYLQQS Full view	Length652	Functional ClassificationIIIc	DiseaseCancer	BrandZevalin	CompanySpectrum Pharmaceuticals B.V.	Physical AppearanceColourless Solution	Route of AdministartionIntravenous	CategoryAntibody, Immunosuppressive Agents	TargetB-lymphocyte antigen CD20, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c
ID1848	ThPPIDTh1236	NameSipuleucel-T	Peptide SequenceNA Full view	Length0	Functional ClassificationIIIc	DiseaseCancer	BrandProvenge	CompanyNA	Physical AppearanceSolution	Route of AdministartionIntravenous	CategoryAntineoplastic and Immunomodulating Agents	TargetProstatic acid phosphatase